Application of Ultrasound Combined with Microbubbles for Cancer Therapy
At present, cancer is one of the leading causes of death worldwide. Treatment failure remains one of the prime hurdles in cancer treatment due to the metastatic nature of cancer. Techniques have been developed to hinder the growth of tumours or at least to stop the metastasis process. In recent years, ultrasound therapy combined with microbubbles has gained immense success in cancer treatment. Ultrasound-stimulated microbubbles (USMB) combined with other cancer treatments including radiation therapy, chemotherapy or immunotherapy has demonstrated potential improved outcomes in various in vitro and in vivo studies. Studies have shown that low dose radiation administered with USMB can have similar effects as high dose radiation therapy. In addition, the use of USMB in conjunction with radiotherapy or chemotherapy can minimize the toxicity of high dose radiation or chemotherapeutic drugs, respectively. In this review, we discuss the biophysical properties of USMB treatment and its applicability in cancer therapy. In particular, we highlight important preclinical and early clinical findings that demonstrate the antitumour effect combining USMB and other cancer treatment modalities (radiotherapy and chemotherapy). Our review mainly focuses on the tumour vascular effects mediated by USMB and these cancer therapies. We also discuss several current limitations, in addition to ongoing and future efforts for applying USMB in cancer treatment.
Top-30
Journals
|
1
2
3
4
5
|
|
|
Cancers
5 publications, 10.64%
|
|
|
Pharmaceutics
2 publications, 4.26%
|
|
|
Mendeleev Communications
2 publications, 4.26%
|
|
|
Ultrasound in Medicine and Biology
2 publications, 4.26%
|
|
|
Ultrasonics Sonochemistry
2 publications, 4.26%
|
|
|
Micromachines
1 publication, 2.13%
|
|
|
Frontiers in Pharmacology
1 publication, 2.13%
|
|
|
Nano Today
1 publication, 2.13%
|
|
|
Free Radical Biology and Medicine
1 publication, 2.13%
|
|
|
MedComm – Oncology
1 publication, 2.13%
|
|
|
Chemical Society Reviews
1 publication, 2.13%
|
|
|
Toxicology and Applied Pharmacology
1 publication, 2.13%
|
|
|
Nanoscale
1 publication, 2.13%
|
|
|
AAPS PharmSciTech
1 publication, 2.13%
|
|
|
Nature Reviews Materials
1 publication, 2.13%
|
|
|
Fundamental Research
1 publication, 2.13%
|
|
|
Frontiers in Chemical Biology
1 publication, 2.13%
|
|
|
Oral Oncology Reports
1 publication, 2.13%
|
|
|
PLoS Medicine
1 publication, 2.13%
|
|
|
Advanced Materials
1 publication, 2.13%
|
|
|
Advanced healthcare materials
1 publication, 2.13%
|
|
|
Cancer Medicine
1 publication, 2.13%
|
|
|
International Journal of Nanomedicine
1 publication, 2.13%
|
|
|
International Journal of Molecular Sciences
1 publication, 2.13%
|
|
|
International Journal of Radiation Biology
1 publication, 2.13%
|
|
|
Radiotherapy and Oncology
1 publication, 2.13%
|
|
|
Journal of Medical Imaging and Radiation Oncology
1 publication, 2.13%
|
|
|
Ultrasonics
1 publication, 2.13%
|
|
|
Investigative Radiology
1 publication, 2.13%
|
|
|
1
2
3
4
5
|
Publishers
|
2
4
6
8
10
12
14
|
|
|
Elsevier
14 publications, 29.79%
|
|
|
MDPI
10 publications, 21.28%
|
|
|
Wiley
5 publications, 10.64%
|
|
|
Springer Nature
4 publications, 8.51%
|
|
|
Frontiers Media S.A.
2 publications, 4.26%
|
|
|
Royal Society of Chemistry (RSC)
2 publications, 4.26%
|
|
|
OOO Zhurnal "Mendeleevskie Soobshcheniya"
2 publications, 4.26%
|
|
|
Taylor & Francis
2 publications, 4.26%
|
|
|
American Chemical Society (ACS)
2 publications, 4.26%
|
|
|
Institute of Electrical and Electronics Engineers (IEEE)
1 publication, 2.13%
|
|
|
Public Library of Science (PLoS)
1 publication, 2.13%
|
|
|
Ovid Technologies (Wolters Kluwer Health)
1 publication, 2.13%
|
|
|
Radiological Society of North America (RSNA)
1 publication, 2.13%
|
|
|
2
4
6
8
10
12
14
|
- We do not take into account publications without a DOI.
- Statistics recalculated weekly.